Format

Send to

Choose Destination
Sci Rep. 2016 Jul 13;6:29506. doi: 10.1038/srep29506.

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.

Author information

1
Division of Genetics and Epidemiology, The Institute of Cancer Research, London UK.
2
Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London UK.
3
The Gynaecological Cancer Unit, The Royal Marsden NHS Foundation Trust, London UK.
4
TGLclinical, The Institute of Cancer Research, London UK.
5
Oxford University NHS Hospital Trust, Oxford UK.

Abstract

Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing and the shortcomings of current pathways to access testing. Approximately 15% of ovarian cancer patients have a germline BRCA1 or BRCA2 mutation which has substantial implications for their personal management and that of their relatives. Unfortunately, in most countries, routine implementation of BRCA testing for ovarian cancer patients has been inconsistent and largely unsuccessful. We developed a rapid, robust, mainstream genetic testing pathway in which testing is undertaken by the trained cancer team with cascade testing to relatives performed by the genetics team. 207 women with ovarian cancer were offered testing through the mainstream pathway. All accepted. 33 (16%) had a BRCA mutation. The result informed management of 79% (121/154) women with active disease. Patient and clinician feedback was very positive. The pathway offers a 4-fold reduction in time and 13-fold reduction in resource requirement compared to the conventional testing pathway. The mainstream genetic testing pathway we present is effective, efficient and patient-centred. It can deliver rapid, robust, large-scale, cost-effective genetic testing of BRCA1 and BRCA2 and may serve as an exemplar for other genes and other diseases.

PMID:
27406733
PMCID:
PMC4942815
DOI:
10.1038/srep29506
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center